Taro Pharmaceutical Industries, Ltd.July 11, 2019

FDA 483 - Taro Pharmaceutical Industries, Ltd. - July 11, 2019

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Taro Pharmaceutical Industries, Ltd.

Record Details

An FDA inspection of Taro Pharmaceutical Industries, Ltd. in Haifa, Israel, revealed a significant quality system deficiency. The firm failed to adequately investigate unexplained discrepancies and batch failures, specifically by not extending investigations to other batches of the same drug product. This lapse resulted in the release and distribution of potentially compromised drug product without proper risk assessment or testing.

Company: Taro Pharmaceutical Industries, Ltd.
Inspection Date: July 11, 2019
Product Type: Drugs
Office: Office of Biological Products Operations - Division I
People: Walden H. Lee (Chemist/Investigator - Pharmaceutical Quality)
Yvesna Blaise

Open in Dashboard

ID · 44cf6f3a-f2c6-40a3-9ff7-7b622a9d7d8b